No products in the cart
Fragment 176-191 and its Uses in Fat Loss
Fragment 176-191 is a synthetic peptide fragment of human growth hormone (HGH). It spans from the 176th to the 191st amino acid residues of the human growth hormone. The fragment comprises an additional tyrosine amino acid residue apart from amino acids 177-191. Research has shown that Frag 176-191, a synthetic Growth Hormone Releasing Hormone (GHRH) agonist, is a strong catalyst for the catabolism of adipocytes. Interestingly, in 1959, human growth hormone was first associated with fat metabolism. Fragment 176-191 and Fat Reduction.
Fragment 176-191 exhibits a unique property to stimulate the metabolism of adipose tissue. Research findings reveal that the molecule AOD9604 is more effective in triggering the burning of fat than AOD9401, which preceded it. It follows the same mechanistic pathway for a fat breakdown as HGH. It also inhibits the conversion of food rich in fat into body fat. Clinical research and laboratory findings have led to the above observations concerning the functional capabilities of the peptide fragment.
Long-term administration of Frag 176-191 in mice has successfully reduced the fat burden in the treated animals through induction of weight loss. The precise reason for this effect is not yet completely understood. However, scientists opine that the binding of the peptide to beta(3)-adrenergic receptors on the surface of white adipose tissues triggers the fat metabolism process. These receptors are well known to be associated with the metabolism of fat in the body. The peptide binding to the cognate receptors induces downstream signaling for mobilizing the stored fat cells to a usable state by increasing the rate of metabolism. Interestingly, mice that genetically lack β-3-adrenergic receptors also have undergone fat loss, possibly through apoptosis of the white adipose tissues. Recent findings have shown that the peptide can also decrease body fat in the mid-abdomen of research subjects who have an average build or are overweight or obese.
Frag 176-191 and Cardiac Disease
Frag 176-191 indirectly improves cardiac health by mobilizing fat and reducing obesity. It thus reduces the chances of cardiac disease caused by obesity. The peptide improves cardiac conditions by other mechanisms as well. These pathways are independent of β-3-adrenergic receptors and contribute to improving general metabolism, leading to improved cardiac health.
Joint Pain and Function
Studies involving Frag 176-191 have demonstrated that it helps to improve cartilage growth. Directly introducing the peptide into arthritic joints in rats improves pain management, decreases movement disability, and enhances general quality of life. The effect is enhanced in conjunction with other existing therapies. Clinical examination and microscopic cartilage structure analysis in the affected joints have shown positive results upon Fragment 176-191 treatment of osteoarthritis. This highlights that applying this peptide can be beneficial in both the prevention and treatment of osteoarthritis.
Other positive features of fragment 176-191
The peptide has shown other relevant physiological effects, apart from fat metabolism. As per studies, it improves bone mineral density and sleeps patterns. Studies have also revealed that Fragment 176-191 enhances expression levels of IGF-1. IGF-1 mediates anti-aging effects like the human growth hormone.
Storage of fragment 176-191 peptides
It is recommended to use unopened vials of fragments 176-191 within 36 months. Once the peptide gets reconstituted, it has a shelf life of 14 days and should be used up within that span. The peptide requires a storage temperature between 2°C and 8°C.
Buy Fragment 176-191
The integrity of the research using the peptide can be ensured by purchasing products of USA origin. The quality of the product from BiotechPeptides has been ensured through HPLC and Mass Spectrometry analysis. It is usually available in 5mg or 10mg vials. The peptide is packaged in lyophilized powder form.
Multiple kinds of research have proven that fragments 176-191 of USA origin are beneficial in treating obesity and general reduction of body fat. The peptide also happens to overcome the adverse effects of Human Growth Hormone and is considered safer than HGH. As per the scientific studies conducted on animal models, the use of the peptide over a span of 30 days in animal models has led to a significant decrease in body fat in the treated animals. The peptide has not demonstrated any serious adverse effect as long as it is administered within limits of permissible dosage. At present, Fragment 176-191 can be procured and used for academic research purpose only. It is yet to be approved for clinical administration.
Disclaimer: The products mentioned are not for human or animal consumption. All the information shared in this article is for educational purposes only.
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.